CTOs on the Move

MycoWorks

www.mycoworks.com

 
In 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco-based biomaterials company dedicated to bringing new mycelium-grown materials to the world. MycoWorks` patented Fine Mycelium™ technology, an advanced manufacturing platform and breakthrough in materials science, engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled beauty, handfeel, strength and durability. The company`s flagship material- Reishi™ - is a new category of material for the world`s best luxury brands.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mycoworks.com
  • 669 Grand View Avenue
    San Francisco, CA USA 94608
  • Phone: 510.479.0060

Executives

Name Title Contact Details
Maud Ohler
Vice President of Technology Development Profile

Funding

MycoWorks raised $17M on 02/25/2020
MycoWorks raised $45M on 11/17/2020
MycoWorks raised $123M on 01/12/2022

Similar Companies

Receptor Life Sciences

Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.

Ganeden Biotech

Ganeden Biotech is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cresilon Inc

Recognizing the importance of managing a traumatic bleed quickly and effectively, Joe Landolina and Isaac Miller founded Cresilon, Inc. based on the hemostatic plant-based gel technology Joe invented while experimenting in the lab. Cresilon has since grown into a biotechnology company headquartered in Brooklyn, New York, commercializing our medical device technology in the animal health, trauma care, and surgical markets.

BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.

AuraSense Therapeutics

AuraSense Therapeutics (AST) is a biopharmaceutical company developing first-in-class therapies based upon its proprietary Spherical Nucleic Acid (SNA) gene regulation and immune modulation strategies. AST is leading the translation of SNA constructs as innovative medicines with a core focus on debilitating diseases with limited or no treatment options. AuraSense Therapeutics' uniquely engineered SNA™ constructs possess attractive biocompatibility and versatility as therapeutics and hold great promise for combating the most life-threatening diseases, including many forms of cancer, infectious disease, and skin conditions.